CD274 and non-small cell lung carcinoma: Since 2015, immune checkpoint inhibitors targeting programmed cell death protein (death-ligand) 1 [PD-(L)1] and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have begun to receive approval from the U.S. Food and Drug Administration (FDA) for advanced NSCLC.